| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO | 4.6% | $22,692,662 | 70,914,570 | BAILLIE GIFFORD & CO | 31 Dec 2024 | |||
| EcoR1 Capital, LLC | 4.2% | $3,960,000 | 66,000,000 | EcoR1 Capital, LLC | 15 Aug 2025 | |||
| Long Focus Capital Management, LLC | 8% | $6,558,206 | 20,494,393 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 31 Dec 2024 | |||
| New Enterprise Associates 14, L.P. | 0% | $0.24 | 4 | New Enterprise Associates 14, L.P. | 15 Aug 2025 |
As of 30 Sep 2025, 54 institutional investors reported holding 42,101,464 shares of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY). This represents 2.7% of the company’s total 1,571,428,571 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$25,973 | $0.05 | 0 |
| 2025 Q3 | 42,101,464 | $5,465,824 | -$18,296,164 | $0.13 | 54 |
| 2025 Q2 | 115,567,681 | $27,687,316 | -$90,786 | $0.24 | 62 |
| 2025 Q1 | 116,071,575 | $22,853,519 | -$8,159,305 | $0.20 | 66 |
| 2024 Q4 | 124,375,303 | $66,996,110 | -$30,508,012 | $0.54 | 77 |
| 2024 Q3 | 151,690,402 | $144,141,106 | -$2,309,668 | $0.95 | 80 |
| 2024 Q2 | 153,890,194 | $150,022,429 | -$8,878,719 | $0.97 | 75 |
| 2024 Q1 | 162,072,769 | $256,066,400 | +$33,065,585 | $1.58 | 77 |
| 2023 Q4 | 143,570,255 | $113,849,283 | -$3,677,784 | $0.79 | 75 |
| 2023 Q3 | 148,300,551 | $115,678,530 | +$2,660,956 | $0.78 | 76 |
| 2023 Q2 | 144,688,047 | $133,835,785 | +$26,554,425 | $0.92 | 83 |
| 2023 Q1 | 115,955,853 | $126,383,143 | +$2,107,801 | $1.09 | 62 |
| 2022 Q4 | 113,867,553 | $166,237,072 | +$542,274 | $1.46 | 63 |
| 2022 Q3 | 113,834,640 | $122,362,454 | -$1,601,132 | $1.08 | 57 |
| 2022 Q2 | 114,642,744 | $194,888,762 | +$7,483,288 | $1.70 | 68 |
| 2022 Q1 | 108,670,758 | $223,856,646 | -$22,118,947 | $2.06 | 71 |
| 2021 Q4 | 113,462,662 | $425,501,139 | -$9,030,529 | $3.75 | 78 |
| 2021 Q3 | 111,578,417 | $576,856,373 | +$3,017,411 | $5.17 | 90 |
| 2021 Q2 | 111,675,845 | $475,736,700 | -$26,235,400 | $4.26 | 80 |
| 2021 Q1 | 117,483,220 | $623,818,340 | -$3,884,137 | $5.31 | 81 |
| 2020 Q4 | 118,170,022 | $636,931,652 | -$92,067,740 | $5.39 | 82 |
| 2020 Q3 | 129,660,816 | $1,034,539,966 | +$4,536,463 | $7.98 | 73 |
| 2020 Q2 | 128,233,056 | $1,283,617,211 | +$368,630,996 | $10.01 | 74 |
| 2020 Q1 | 93,842,793 | $255,252,329 | +$79,471,512 | $2.72 | 43 |
| 2019 Q4 | 64,871,304 | $77,847,000 | -$4,188,198 | $1.20 | 33 |
| 2019 Q3 | 68,105,678 | $102,836,183 | -$1,396,156 | $1.51 | 40 |
| 2019 Q2 | 68,201,500 | $274,160,898 | -$5,116,443 | $4.02 | 52 |
| 2019 Q1 | 69,063,579 | $296,975,029 | -$2,782,725 | $4.30 | 61 |
| 2018 Q4 | 69,083,013 | $397,178,060 | -$2,952,007 | $5.75 | 72 |
| 2018 Q3 | 65,498,777 | $887,959,093 | +$131,554,450 | $13.56 | 89 |
| 2018 Q2 | 55,906,827 | $663,498,251 | -$2,398,891 | $11.87 | 86 |
| 2018 Q1 | 56,164,712 | $630,580,601 | +$52,076,139 | $11.23 | 74 |
| 2017 Q4 | 51,280,439 | $342,330,008 | +$1,991,407 | $6.68 | 66 |
| 2017 Q3 | 50,806,697 | $415,709,914 | +$29,127,748 | $8.19 | 63 |
| 2017 Q2 | 48,135,770 | $215,671,000 | +$37,680,358 | $4.49 | 51 |
| 2017 Q1 | 39,767,515 | $218,419,138 | +$54,884,349 | $5.51 | 48 |
| 2016 Q4 | 29,814,799 | $120,734,000 | -$7,125,550 | $4.05 | 37 |
| 2016 Q3 | 30,947,697 | $218,180,000 | -$7,772,917 | $7.05 | 45 |
| 2016 Q2 | 31,867,413 | $259,715,000 | -$1,113,373 | $8.15 | 45 |
| 2016 Q1 | 32,004,999 | $260,217,000 | +$87,357,118 | $8.13 | 47 |
| 2015 Q4 | 20,609,672 | $248,552,000 | +$83,845,114 | $12.06 | 47 |
| 2015 Q3 | 13,750,382 | $164,591,000 | -$63,322,495 | $11.97 | 40 |
| 2015 Q2 | 19,188,683 | $351,730,000 | +$342,953,020 | $18.33 | 44 |